Literature DB >> 17579089

Fullerene nanomaterials inhibit the allergic response.

John J Ryan1, Henry R Bateman, Alex Stover, Greg Gomez, Sarah K Norton, Wei Zhao, Lawrence B Schwartz, Robert Lenk, Christopher L Kepley.   

Abstract

Fullerenes are a class of novel carbon allotropes that may have practical applications in biotechnology and medicine. Human mast cells (MC) and peripheral blood basophils are critical cells involved in the initiation and propagation of several inflammatory conditions, mainly type I hypersensitivity. We report an unanticipated role of fullerenes as a negative regulator of allergic mediator release that suppresses Ag-driven type I hypersensitivity. Human MC and peripheral blood basophils exhibited a significant inhibition of IgE dependent mediator release when preincubated with C(60) fullerenes. Protein microarray demonstrated that inhibition of mediator release involves profound reductions in the activation of signaling molecules involved in mediator release and oxidative stress. Follow-up studies demonstrated that the tyrosine phosphorylation of Syk was dramatically inhibited in Ag-challenged cells first incubated with fullerenes. In addition, fullerene preincubation significantly inhibited IgE-induced elevation in cytoplasmic reactive oxygen species levels. Furthermore, fullerenes prevented the in vivo release of histamine and drop in core body temperature in vivo using a MC-dependent model of anaphylaxis. These findings identify a new biological function for fullerenes and may represent a novel way to control MC-dependent diseases including asthma, inflammatory arthritis, heart disease, and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579089     DOI: 10.4049/jimmunol.179.1.665

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.

Authors:  Sarah K Norton; Dayanjan S Wijesinghe; Anthony Dellinger; Jamie Sturgill; Zhiguo Zhou; Suzanne Barbour; Charles Chalfant; Daniel H Conrad; Christopher L Kepley
Journal:  J Allergy Clin Immunol       Date:  2012-06-02       Impact factor: 10.793

Review 2.  Nanoparticles and the immune system.

Authors:  Banu S Zolnik; Africa González-Fernández; Nakissa Sadrieh; Marina A Dobrovolskaia
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

Review 3.  Understanding engineered nanomaterial skin interactions and the modulatory effects of ultraviolet radiation skin exposure.

Authors:  Samreen Jatana; Lisa A DeLouise
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-10-03

Review 4.  Nanoparticles and direct immunosuppression.

Authors:  Terrika A Ngobili; Michael A Daniele
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

5.  Immune responses to engineered nanomaterials: current understanding and challenges.

Authors:  Nasser B Alsaleh; Jared M Brown
Journal:  Curr Opin Toxicol       Date:  2017-11-24

6.  Influence of physicochemical properties of silver nanoparticles on mast cell activation and degranulation.

Authors:  Abdullah A Aldossari; Jonathan H Shannahan; Ramakrishna Podila; Jared M Brown
Journal:  Toxicol In Vitro       Date:  2015-02       Impact factor: 3.500

Review 7.  From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.

Authors:  Matthew J Smith; Jared M Brown; William C Zamboni; Nigel J Walker
Journal:  Toxicol Sci       Date:  2014-01-15       Impact factor: 4.849

Review 8.  Immunotoxicological impact of engineered nanomaterial exposure: mechanisms of immune cell modulation.

Authors:  Xiaojia Wang; Shaun P Reece; Jared M Brown
Journal:  Toxicol Mech Methods       Date:  2013-01-17       Impact factor: 2.987

Review 9.  Current understanding of interactions between nanoparticles and the immune system.

Authors:  Marina A Dobrovolskaia; Michael Shurin; Anna A Shvedova
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 10.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.